Literature DB >> 11906438

In situ duct carcinoma of the breast: clinical and histopathologic factors and association with recurrent carcinoma.

N A Miller1, J A Chapman, E B Fish, M A Link, E Fishell, B Wright, H L Lickley, D R McCready, W M Hanna.   

Abstract

There has been a recent increase in the diagnosis of in situ duct carcinoma of the breast (DCIS) as a result of mammographic screening. DCIS is heterogeneous in appearance and likely in prognosis. There is no generally accepted model to predict progression to invasive carcinoma. We investigated the prognostic effect of clinical presentation and pathologic factors for women diagnosed with primary DCIS. A cohort of 124 patients was accrued between 1979 and 1994 and was followed to 1997; 78 had DCIS detected mammographically, and 88 underwent lumpectomy alone. In this article, we provide details about characteristics affecting the choice of primary therapeutic modality, and we examine the effects of factors on progression for the two patient subgroups. Presentation with bloody nipple discharge was associated with a significant increase in DCIS recurrence (p=0.07). The pattern of duct distribution was important: DCIS in which the involved ducts were more widely separated had a significantly greater recurrence of DCIS than when the involved ducts were more concentrated (p=0.08 for mammographically detected DCIS, p=0.07 for patients who underwent lumpectomy alone). For mammographically detected DCIS, younger patients had more DCIS recurrence (p=0.07). We found considerable heterogeneity in nuclear grade; 50% of patients exhibited more than one grade. Nuclear grade, necrosis, and architecture were not significantly associated with either recurrence of DCIS or development of invasive carcinoma. Longer follow-up will allow further evaluation of the prognostic relevance of the factors assessed.

Entities:  

Mesh:

Year:  2001        PMID: 11906438     DOI: 10.1046/j.1524-4741.2001.99124.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  17 in total

Review 1.  How Can Advanced Imaging Be Used to Mitigate Potential Breast Cancer Overdiagnosis?

Authors:  Habib Rahbar; Elizabeth S McDonald; Janie M Lee; Savannah C Partridge; Christoph I Lee
Journal:  Acad Radiol       Date:  2016-03-23       Impact factor: 3.173

2.  Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment.

Authors:  Jing Luo; Brian S Johnston; Averi E Kitsch; Daniel S Hippe; Larissa A Korde; Sara Javid; Janie M Lee; Sue Peacock; Constance D Lehman; Savannah C Partridge; Habib Rahbar
Journal:  Radiology       Date:  2017-09-14       Impact factor: 11.105

3.  Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast?

Authors:  Alfredo Ribeiro-Silva; Leandra N Zamzelli Ramalho; Sérgio Britto Garcia; Sérgio Zucoloto
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

4.  CLASSIFICATION OF TUMOR HISTOPATHOLOGY VIA SPARSE FEATURE LEARNING.

Authors:  Nandita Nayak; Hang Chang; Alexander Borowsky; Paul Spellman; Bahram Parvin
Journal:  Proc IEEE Int Symp Biomed Imaging       Date:  2013-04

Review 5.  Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.

Authors:  Tatyana Shamliyan; Shi-Yi Wang; Beth A Virnig; Todd M Tuttle; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

6.  Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors.

Authors:  David E Axelrod; Naomi Miller; Judith-Anne W Chapman
Journal:  Biomed Inform Insights       Date:  2009-01-01

7.  Can MRI biomarkers at 3 T identify low-risk ductal carcinoma in situ?

Authors:  Habib Rahbar; Sana Parsian; Diana L Lam; Brian N Dontchos; Nicole K Andeen; Mara H Rendi; Constance D Lehman; Savannah C Partridge
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

8.  Heterogeneity Between Ducts of the Same Nuclear Grade Involved by Duct Carcinoma In Situ (DCIS) of the Breast.

Authors:  Naomi A Miller; Judith-Anne W Chapman; Jin Qian; William A Christens-Barry; Yuejiao Fu; Yan Yuan; H Lavina A Lickley; David E Axelrod
Journal:  Cancer Inform       Date:  2010-09-07

9.  Immunohistochemical and proteomic evaluation of nuclear ubiquitous casein and cyclin-dependent kinases substrate in invasive ductal carcinoma of the breast.

Authors:  Piotr Ziółkowski; Elzbieta Gamian; Beata Osiecka; Alexandre Zougman; Jacek R Wiśniewski
Journal:  J Biomed Biotechnol       Date:  2009-12-24

10.  A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.

Authors:  Lawrence J Solin; Robert Gray; Frederick L Baehner; Steven M Butler; Lorie L Hughes; Carl Yoshizawa; Diana B Cherbavaz; Steven Shak; David L Page; George W Sledge; Nancy E Davidson; James N Ingle; Edith A Perez; William C Wood; Joseph A Sparano; Sunil Badve
Journal:  J Natl Cancer Inst       Date:  2013-05-02       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.